Novel regenerative treatments for CNS disorders and cerebral stroke

Biotech start-up company NovaGo is developing human antibodies that stimulate nerve repair and regeneration following a stroke. The company’s lead candidate anti-Nogo-A antibody (NG004) is ready for phase 1 trials, and it is looking for partners to develop it through the clinic.

Like Comment
Page of
Go to the profile of novaGo

novaGo

CEO, NovaGo

NovaGo Therapeutics is a Swiss biotech startup company dedicated to the development of human antibody therapeutics that promote nerve repair and regeneration in brain and retina. NovaGo is pursuing the development of its lead molecule, NG004, in two indications, regenerative therapy for ischemic stroke and novel therapy for diabetic retinopathy.

No comments yet.